期刊
CURRENT OPINION IN IMMUNOLOGY
卷 39, 期 -, 页码 44-51出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2015.12.007
关键词
-
类别
资金
- FEDER funds (EU) from the Instituto de Salud Carlos III [CP03/0111, PI12/02031, PI 08/1265, PI 11/01022, PI11/01386, PI14/01978, PI15/00528, RETIC RD 06/020, RD09/0076/00165, PT13/0010/0039]
- Junta de Andalucia in Spain [CTS-143, CTS-695, CTS-3952, CVI-4740, PI 09/0382]
- Worldwide Cancer Research [15-1166]
- Dutch Cancer Society [UL 2010-4785]
- Worldwide Cancer Research [15-1166] Funding Source: researchfish
Immune escape strategies aimed to avoid T-cell recognition, including the loss of tumor MHC class I expression, are commonly found in malignant cells. Tumor immune escape has proven to have a negative effect on the clinical outcome of cancer immunotherapy, including treatment with antibodies blocking immune checkpoint molecules. Hence, there is an urgent need to develop novel approaches to overcome tumor immune evasion. MHC class I antigen presentation is often affected in human cancers and the capacity to induce upregulation of MHC class I cell surface expression is a critical step in the induction of tumor rejection. This review focuses on characterization of rejection, escape, and dormant profiles of tumors and its microenvironment with a special emphasis on the tumor MHC class I expression. We also discuss possible approaches to recover MHC class I expression on tumor cells harboring reversible/'soft' or irreversible/'hard' genetic lesions. Such MHC class I recovery approaches might well synergize with complementary forms of immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据